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Abstract
Purpose Incidence and prevalence estimates of acrome-
galy in the United States (US) are limited. Most existing
reports are based on European data sources. The objective
of this study was to estimate the annual incidence and
prevalence of acromegaly in a large US managed care
population, overall and stratified by age, sex, and geo-
graphic region, using data from 2008 to 2012.
Methods Using administrative claims data, commercial
health plan enrollees were identified with acromegaly if
they had two or more medical claims with an acromegaly
diagnosis code (ICD-9-CM: 253.09) or one medical claim
with an acromegaly diagnosis code in combination with
one other claim for a pituitary tumor or pituitary procedure.
The first date for an acromegaly-related claim set the index
year. Incidence rates for each year were calculated by
dividing the number of new acromegaly cases by the cal-
culated person-time at risk. Annual prevalence estimates
were calculated by dividing the number with any evidence
of acromegaly by the total number of health plan enrollees
enrolled for at least 1 day during each calendar year.
Incidence and prevalence estimates were stratified by age
(0–17, 18–44, 45–64, 65? years), sex (male, female), and
US geographic region of the health plan (Midwest,
Northeast, South, West).
Results Overall annual incidence rates of acromegaly were
relatively constant across 2008–2012 with *11 cases per
million person-years (PMPY). Rates increased with age,
ranging from 3–8 cases PMPY among children aged 0–17
years old to 9–18 cases PMPY among adults aged 65 and
older. Females had 12 cases PMPY on average compared to
10 cases PMPY among men. On average, the Midwest had
the lowest incidence rates (7 cases PMPY) compared to the
Northeast, South and West (14, 12, and 10 cases PMPY,
respectively). The overall annual prevalence of acromegaly
was relatively constant across the 5 years from 2008 to 2012
with approximately 78 cases per million each year. Annual
prevalence estimates increased with age, ranging from
29–37 cases per million among children aged 0–17 years old
to 148–182 cases per million among adults aged 65 years and
older. Males and females were similarly affected; each with
approximately 77 cases per million each year. The Northeast
and South had the highest prevalence estimates (92 and 89
cases per million, respectively); while the estimates for the
West and Midwest were lower (65 and 57 cases per million,
respectively) each year.
Conclusion This study examined 5 years of recent data to
estimate the incidence and prevalence of acromegaly in a
large geographically-diverse managed care population. The
incidence rates were higher on average than published rates
outside the US (11 vs. 3.3 PMPY), but prevalence esti-
mates were consistent with previous reports. Incidence and
prevalence both increased by age, did not differ for males
and females, and varied slightly by US geographic region.
The age and sex distribution of the selected population
matched the known epidemiology of the disease. Using a
claims-based approach, this analysis only captured acro-
megaly cases with an acromegaly-related medical claim.
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As a result, these estimates may underestimate the inci-
dence and prevalence of acromegaly in US commercial
health plans as they did not include individuals who were
undiagnosed, in remission, undertreated, or not monitored
during the study period. At the same time, these estimates
may be viewed as an upper bound on the incidence of
acromegaly in the US as the estimates did not include
individuals who were in other health plans or uninsured
during the study period. Additional evaluations are needed
to identify the full extent of acromegaly in the US.
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Introduction
Most incidence and prevalence estimates of acromegaly
come from studies conducted in countries outside of the
United States (US), often using data from disease registries
or national health care systems. Population-based lifetime
data are ideal for tracking the development and existence
of rare diseases such as acromegaly. However, estimating
the presence of acromegaly in any data source is compli-
cated by its insidious nature that changes slowly over time
and often mimics many common aging conditions such as
diabetes and heart disease. The signs and symptoms of
acromegaly are so commonplace among the general pop-
ulation that diagnosis is often delayed an average of
4–7 years after the onset of excessive growth hormone
(GH) secretion in adults; but in children, the disease is
much less likely to go unnoticed due to their abnormally
dynamic growth in physical stature [1].
Most published estimates of acromegaly are fairly
consistent with each other but dated. While incidence rates
published across Europe, Asia, and New Zealand are
remarkably similar, ranging around 2–4 per million per
year, the majority are also more than 10 years old [2–11].
Prevalence estimates of acromegaly vary more, ranging
from 30 to 100 per million and cover a similar time span
with most data collected before 2004 [2–9]. A recent study
by Hoskuldsdottir [12] examined Icelandic data from 1955
to 2013 (the most expansive and recent data collected to
date) and found slightly higher estimates than other non-
US reports (7.7 million new cases of acromegaly per year
and 134 per million prevalent cases) [12].
To date, all epidemiologic studies are consistent with
respect to the 1:1 sex distribution, mean age of diagnosis
around mid-forties, 1:3 micro to macro adenomas, and the
approximate rates of surgical success with up to 90 % for
micro adenomas and\60 % for macro adenomas when in
expert pituitary surgical care [13]. However, little is pub-
lished about acromegaly in the US. Although there is no
universal health care system in the US, large samples of
acromegaly patients may be found in private health insur-
ance databases. The objective of this research was to
estimate the annual incidence and prevalence of acrome-
galy from 2008 to 2012 in a large US managed care pop-
ulation using administrative claims data.
Methods
Source population
The source population was derived from a large health
insurance database, which contains medical and pharmacy
claims, and enrollment information from a geographically-
diverse group of health plans in the US. Dating back to
1993, the database includes data on more than 123 million
US health plan enrollees over time.
The medical claims in the database for professional and
facility services include information on diagnoses, reported
with International Classification of Diseases, 9th Revision,
Clinical Modification (ICD-9-CM) diagnosis codes, and
procedures, reported with ICD-9-CM, Current Procedural
Terminology, Version 4 (CPT-4), and Healthcare Common
Procedure Coding System (HCPCS) procedure codes. The
medical claims also include site of service codes and health
plan- and patient-paid amounts for services received.
Outpatient pharmacy claims include national drug codes
(NDC), drug dosage form, fill date, health plan- and
patient-paid amounts for dispensed medications. All
administrative claims data for this study were de-identified
and compliant with the provisions of the health insurance
portability and accountability act of 1996.
Acromegaly case identification
The study population included children and adult commer-
cial health plan enrollees in the database between July 1,
2000 and June 30, 2012 (identification period) who met one
of the following three acromegaly selection criteria: (1) had
at least two medical claims on separate dates with an acro-
megaly diagnosis code (ICD-9-CM: 253.09); or (2) had one
medical claim with an acromegaly diagnosis code in com-
bination with one medical claim with a pituitary tumor
diagnosis code (ICD-9-CM: 237.09); or (3) had one medical
claim with an acromegaly diagnosis code in combination
with one medical claim for a pituitary surgery (hypophy-
sectomy) or stereotactic radiosurgery (radiation) procedure
(Supplement Table A).
Person-time at risk
Observation time for acromegaly began on the date of
health plan entry. Person-time at risk continued to accrue
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until the earliest of: acromegaly onset, death, disenrollment
from the health plan, or study cut-off, December 31, 2012.
The date of acromegaly onset was defined as the first date
for an acromegaly-related claim (i.e., a claim with a
diagnosis or procedure code for acromegaly, pituitary
tumor, hypophysectomy, or radiation) on or after January
1, 2000. The date of acromegaly onset also set the index
year. Years prior to the index year were defined as acro-
megaly-free and years following the index year were
defined as having a history of the disease.
Incidence and prevalence analysis
Annual incidence and prevalence estimates of acromegaly
from 2008 to 2012 were derived from the managed care
population. Incidence rates were calculated by dividing the
number of new acromegaly cases (i.e., no evidence of
acromegaly during the 6 months prior to the index claim)
by the total time at risk during each calendar year. All
incidence rates were reported as the number of cases per
one million (1,000,000) person-years at risk. Prevalence
was calculated by dividing the number with an acrome-
galy-related claim during each calendar year or any time
prior by the total number continuously enrolled in the
health plan for the entire calendar year. Incidence and
prevalence estimates were stratified by age (0–17, 18–44,
45–64, 65? years), sex (male, female), and US geographic
region of the health plan (Midwest, Northeast, South,
West).
All study variables were summarized descriptively using
SAS v9.2 (SAS Institute, Cary, NC).
Results
Of the more than 50 million commercial health plan
enrollees in the database from 2000 to 2012, 4090 had at
least one claim with an acromegaly diagnosis code and
2241 had the additional criteria suggestive of true acro-
megaly (i.e., additional acromegaly services, a pituitary
tumor or procedure) (Fig. 1). Hence, overall prevalence of
acromegaly in the database from 2000 to 2012 was esti-
mated to be 45 per million. These subjects had a mean age
of 41 years and a near equal sex distribution (48 % males
vs. 52 % females). The geographic distribution mirrored
the health plan with the majority in the South (55 %) and
Midwest (22 %), and smaller proportions in the West
(13 %) and Northeast (10 %).
Incidence and prevalence results
Annual incidence rates of acromegaly were relatively
constant across 2008–2012 with an overall rate of
approximately 11 cases per million person-years (PMPY)
(Fig. 2a and Supplement Table B). Rates increased with
age, ranging from 3–8 cases PMPY among children aged
0–17 years old to 9–18 cases PMPY among adults 65 years
and older (Fig. 2b). Males and females were similarly
affected over time (Fig. 2c). Females had 12 cases PMPY
on average compared to 10 cases PMPY among men. On
average, Midwest health plans had the lowest incidence
rates (7 cases per million PY) compared to health plans in
the Northeast (14 cases PMPY), South (12 cases PMPY),
and West (10 cases PMPY) (Fig. 2d).
Prevalence estimates for acromegaly were also fairly
constant across the 5 years, with approximately 78 cases per
million each year (Fig. 3a and Supplement Table C). Annual
prevalence estimates increased with age, ranging from
29–37 cases per million among children aged 0–17 years to
148–182 cases per million among adults aged 65 years and
older (Fig. 3b). As with incidence, prevalence estimates for
males and females were similar, each with approximately 77
cases per million each year (Fig. 3c). Health plans in the
Northeast and South had the highest prevalence (92 and 89
cases per million, respectively), while health plans in the
West and Midwest were lower (65 and 57 cases per million,
respectively) each year (Fig. 3d).
Discussion
To our knowledge, this is the first study to assess the
incidence and prevalence of acromegaly in a large geo-
graphically-diverse managed care population in the US.
This study used administrative claims data to estimate the
incidence and prevalence of acromegaly between 2008 and
2012. The incidence rates were higher on average than
published rates outside the US (11 vs. 3.3 per million
person-years), but prevalence estimates were consistent
with previous reports. Overall, the incidence and preva-
lence estimates increased by age, did not differ for males
and females, and varied by US geographic region. The age
and sex distribution of the selected population matched the
known epidemiology of the disease.
It is not surprising that our incidence rates differed from
studies outside the US, given the vast differences in the
methods used to collect health data around the world.
There are several reasons that may explain the difference
observed between our incidence estimates and the non-US
studies. First, the sample of commercially-insured health
plan enrollees in the database primarily includes working-
age adults in the US who are more likely to be near the
mean age of disease onset than the national populations
included in non-US studies. Second, since administrative
claims data are collected for the purposes of billing rather
than research, it is possible that a diagnosis code on a
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medical claim may not indicate the presence of actual
disease. Although only non-diagnostic medical claims were
used to identify acromegaly (claims from laboratories and
diagnostic testing centers may include ‘‘rule-out’’ proce-
dures for diagnoses not yet confirmed), it is still possible
that acromegaly may have been miscoded or misidentified
on claims, which could have increased the reported inci-
dence rates. Third, this analysis required individuals to
have at least one health care service to be included in the
incidence calculations, which suggests that the reported
incidence rates may have been lower if the population had
included healthier individuals with no health care use as
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Fig. 2 a Incidence—overall. b Incidence by age. c Incidence by sex. d Incidence by geographic region
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well. At the same time, this analysis required at least two
medical claims to identify acromegaly cases, which sug-
gests that the reported incidence may have been even
higher as the estimates did not identify individuals with
acromegaly who were undiagnosed, in remission, under-
treated, or not monitored during the study period. Other
limitations to consider when interpreting these results
include the source population and its generalizability. As
noted above, the study data came from a geographically-
diverse managed care population, which means the results
are primarily applicable to populations that receive their
care through similar delivery systems across the US.
However, this still leaves out a significant proportion of the
US population, many of whom have other forms of health
insurance such as Medicare, Medicaid, Tricare, or none at
all. In comparison, non-US surveys typically are based on
disease registries or health systems that collect extensive
national data like Finland and New Zealand or offer indi-
viduals ongoing access to medical coverage throughout life
such as the National Health Service (NHS) in the United
Kingdom [2, 11]. In spite of these differences, this study
found US prevalence estimates that fit within the range of
prior research. Although given the study’s selection crite-
ria, they more likely estimate the prevalence of acromegaly
patients with active disease.
To calculate the incidence and prevalence of acromegaly
correctly it is important to know not only who was diagnosed,
but also when they were diagnosed and the current disease
status (e.g., active vs. inactive disease). While US health plan
databases have the ability to track individuals longitudinally,
their populations can change frequently as individuals enroll
and disenroll from health plans over time. As a result,
acromegaly-related care received outside of the health plan is
not always included in the database or may be excluded when
analyzing individual cuts of the data (e.g., when using a
subset of data between 2008 and 2012). This study sought to
overcome these limitations by requiring at least a 6-month
continuous enrollment period and including all medical
claims in the database dating back to January 2000 to check
for acromegaly history regardless of enrollment status.
Lastly, to identify our sample without clinical data such as
the date of diagnosis, substantial emphasis was placed on
multiple pathways to acromegaly case identification. How-
ever, no medical chart review was conducted to validate our
claims-based definition. Given that acromegaly is chal-
lenging to diagnose and cannot be confirmed using claims
data alone, future research should include clinical data from
medical charts or electronic health records to validate the
algorithm used to identify acromegaly patients in adminis-
trative claims databases.
Conclusion
This study examined 5 years of recent data to estimate the
incidence and prevalence of acromegaly in a large geo-
graphically-diverse managed care population in the US.
The incidence rates were higher on average than published
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Fig. 3 a Prevalence—overall. b Prevalence by age. c Prevalence by sex. d Prevalence by geographic region
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rates outside the US (11 vs. 3.3 per million person-years),
but prevalence estimates (*78 cases per million each year)
were consistent with previous reports. Overall, the inci-
dence and prevalence estimates increased by age, did not
differ for males and females, and varied slightly by US
geographic region. The age and sex distribution of the
selected population matched the known epidemiology of
the disease. Using a claims-based approach, this analysis
only captured acromegaly cases with an acromegaly-
related medical claim. As a result, these estimates may
underestimate the incidence and prevalence of acromegaly
in US commercial health plans as they did not include
individuals who were undiagnosed, in remission, under-
treated, or not monitored during the study period. At the
same time, these estimates may be viewed as an upper
bound on the incidence of acromegaly in the US as the
estimates did not include individuals who were in other
health plans or uninsured during the study period. While
the claims-based algorithm was not validated with a med-
ical chart review, this study did find data that matched the
known epidemiology of the disease. Additional evaluations
are needed to identify the full extent of acromegaly in the
US.
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